يعرض 321 - 340 نتائج من 14,807 نتيجة بحث عن '(( significant increase decrease ) OR ( significantly ((mediate decrease) OR (mean decrease)) ))', وقت الاستعلام: 0.69s تنقيح النتائج
  1. 321
  2. 322
  3. 323
  4. 324
  5. 325
  6. 326
  7. 327
  8. 328
  9. 329
  10. 330
  11. 331
  12. 332
  13. 333
  14. 334

    BMI curve for LSES. حسب Krystal Hunter (6820052)

    منشور في 2025
    الموضوعات:
  15. 335

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  16. 336

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  17. 337

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  18. 338
  19. 339
  20. 340

    Raw data of Figs 1–6 in this study. حسب Qi Qi Lu (17721401)

    منشور في 2025
    الموضوعات: